Trial · NCT04903197
Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
NCT04903197, Phase 1, Terminated, Novartis Pharmaceuticals
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma. Trials, record NCT04903197. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04903197
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of VAY736 as Single Agent and in Combination With Select Antineoplastic Agents in Patients With Non-Hodgkin Lymphoma
- NCT number
- NCT04903197
- Status
- Terminated
- Phases
- Phase 1
- Enrollment
- 18 participants, actual
- Lead sponsor
- Novartis Pharmaceuticals
- Conditions
- Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma
- Interventions
- VAY736, lenalidomide
- First posted
- 2021-05-26
- Last updated
- 2026-04-01
- Other registries' IDs
- eudract:2020-005881-32
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Incidence and nature of dose limiting toxicities (DLTs) | 28 days (first cycle of treatment) | Safety and tolerability |
| Primary | Incidence of Adverse events (AEs) and serious adverse events (SAEs) | 4 years | Incidence of AEs and SAEs is defined as number of participants with AEs and SAEs, including changes from baseline in vital signs, electrocardiograms (ECGs) and laboratory results qualifying and reported as AEs. |
| Primary | Number of patients with dose interruptions and dose reductions | 4 years | Safety and tolerability |
| Primary | Dose intensity | 4 years | Safety and tolerability |
| Secondary | Overall response rate (ORR) | 4 years | Efficacy will be assessed by Lugano Classification (FDG-PET/CT scans) |
| Secondary | Best overall response (BOR) rate | 4 years | Efficacy will be assessed by Lugano Classification (FDG-PET/CT scans) |
| Secondary | Area under curve (AUC) for VAY736 and combination partners | 4 years | PK parameters will be derived from serum concentrations |
| Secondary | Maximum observed drug concentration after single dose administration (Cmax) for VAY736 and combination partners | 4 years | PK parameters will be derived from serum concentrations |
| Secondary | Change from baseline in anti-drug antibodies (ADA) | Baseline, 4 years | Blood samples will be collected to detect change in levels of antibodies to VAY736 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04903197
GET https://conductscience.org/api/trials/v1/NCT04903197/registered